1332 results about "Adjuvant therapy" patented technology

The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®.

A mechanical wound therapy (MWT) system includes a connection for a vacuum source, which is routed through an airtight covering to a porous material positioned over the wound. The porous material may be a tubing network interspaced by a netting material constructed of biologically inert or bioabsorbable material. Alternatively, the porous material may be a layered unified dressing in which layers of mesh, netting or thin perforated film are separated and fixedly attached to functional elements of the dressing (e.g., irrigation tubing) or spacers. The vacuum and irrigation systems may be completely separated. An airtight sealing layer or foldable adhesive sealing layer may seal the dressing and facilitate sealing the dressing to the wound margins. Additional modular devices such as a wound approximating system, positive pressure bladders and adjuvant therapy modules as well as enhanced monitoring technology can be added to synergistically increase the capabilities of each dressing.

Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.

The present invention is based on the surprising discovery that agonists of TLR8 are uniquely efficacious in enhancing (e.g. inducing) the immune response of newborns. Thus, agonists of TLR8 serve as both vaccine adjuvants and as adjunctive therapies for acute infection in newborns, preferably the agonist is a TLR8-selective agonist. The immune response induced, or enhanced, in the neonatal host can be, for example, a cytokine immune response and / or a humoral immune response (e.g., antigen-specific).

A mechanical wound therapy (MWT) system includes a connection for a vacuum source, which is routed through an airtight covering to a porous material positioned over the wound. The porous material may be a tubing network interspaced by a netting material constructed of biologically inert or bioabsorbable material. Alternatively, the porous material may be a layered unified dressing in which layers of mesh, netting or thin perforated film are separated and fixedly attached to functional elements of the dressing (e.g., irrigation tubing) or spacers. The vacuum and irrigation systems may be completely separated. An airtight sealing layer or foldable adhesive sealing layer may seal the dressing and facilitate sealing the dressing to the wound margins. Additional modular devices such as a wound approximating system, positive pressure bladders and adjuvant therapy modules as well as enhanced monitoring technology can be added to synergistically increase the capabilities of each dressing.

The invention relates to a noninvasive radiotherapy system for a robot, and belongs to the medical equipment field. The noninvasive radiotherapy system for the robot consists of seven modules, i.e. a radiotherapy planning system, a three-dimensional numerical-control therapy bed, an automatic tracking system for a four-dimensional real-time image, a robot system, a radioactive source, an adjuvant therapy system and an integrated control system, wherein the automatic tracking system for the four-dimensional real-time image consists of a six-freedom-of-degree G-shaped arm real-time image system and an intelligent tracking system; the six-freedom-of-degree G-shaped arm real-time image system is formed by successively connecting a G-shaped arm, a G-shaped arm sliding rail, a G-shaped arm spindle, a G-shaped arm pitch shaft and a G-shaped arm sliding seat; an X ray source and an X ray dynamic flat panel detector are formed into one group, and two groups are correspondingly installed on the G-shaped arm; and the G-shaped arm sliding seat is installed in a rail (9). According to the noninvasive radiotherapy system for the robot, which is disclosed by the invention, the defects of unmatched projection time, time waste and low therapy precision in the prior art are overcome, the precise therapy of the whole body tumor can be carried out, and the cardiovascular disease therapy and the noninvasive regulation of the renal nerve disease can be carried out.

Compositions containing a carrier and microbubles encapsulating one or more gases, preferably oxygen, and methods for making and using the compositions are described herein. The microbubbles contain a lipid envelope formed of at least one base lipid and at least one emulsifying agent. The compositions may be administered to a patient to quickly deliver large amounts of oxygen to the patient's blood supply or directly to a tissue in need of oxygen. The compositions may be administered via injection or as a continuous infusion. The compositions contain a concentrated microbubble suspension, where the suspension contains at least 40 mL oxygen / dL suspension. The microbubbles are preferably less than 20 microns in diameter, more preferably less than 15 microns in diameter. The microbubbles described herein may be administered to a patient in an effective amount to increase in oxygen concentration in the patient's blood, and / or one or more tissues or organs. The microbubbles may be administered alone or in combination with other treatments as an adjuctive therapy.

The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a nucleoside 5′-pyrophosphate pyranoside or analogue, which is defined by general Formula I. The method of the present invention is useful in the treatment or prevention of ocular hypertension, such as found in glaucoma, including primary and secondary glaucoma. The method can be used alone to reduce intraocular pressure. The method can also be used in conjunction with another therapeutic agent or adjunctive therapy commonly used to treat glaucoma to enhance the therapeutic effect of reducing the intraocular pressure. The present invention also provides a novel composition comprising a nucleoside 5′-pyrophosphate pyranoside or analogue.

Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include mirtazapine in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as adjuvant therapy with positive airway pressure (PAP) therapy, thereby lowering the pressure required to maintain airway patency during PAP therapy.

The invention discloses a polypeptide medicament sustained release microsphere or a microcapsule preparation with uniform grain size, a preparation method thereof and application. The average grain size of the microsphere or the microcapsule preparation is between 50 nanometers and 100 microns, and the grain size distribution coefficient CV value is less than 20 percent. The polypeptide medicament has a definite structure, has functions of therapy or adjuvant therapy of type-2 diabetes, and is preferably one or more of GLP-1, Exenatide, Exendin-4 and derivatives and analogs thereof. The microsphere or the microcapsule preparation uses a microsphere or a microcapsule with uniform grain size as a substrate to prepare the polypeptide medicament into a sustained release preparation through an embedding mode, and by changing the grain size of the microsphere or the microcapsule, the sustained release cycle is adjustable between one week and one month, and the microsphere or the microcapsule preparation can be applied to the therapy or the adjuvant therapy of the type-2 diabetes and body weight control. Besides, the microsphere or the microcapsule preparation has the advantages of simple preparation process and mild preparation course, and can protect the biological activity of the embedded polypeptide medicament.

Colorectal cancer patients with operable tumors must decide whether to receive adjuvant therapy after surgical resection in order to reduce their chances of recurrence. Current clinical guidelines are crudely based on the stage of the disease, as well as a few other clinicopathologic features. The instant invention integrates data from these clinicopathologic features with data on multiple biomarkers using advanced informatic methods to provide a far more accurate prediction of recurrence than the current guidelines. The instant invention consists of a panel of biomarker assays plus an algorithm into which the scored biomarker data, as well as standard clinicopathologic data, is entered. A tumor sample from an individual patient is submitted for test, and an individualized report is produced with a prognostic score that accurately reflects the patient's risk of recurrence. This helps guide the patient and his / her oncologist in their choice of whether to receive adjuvant treatment. Low-risk patients are spared the unnecessary toxicities associated with cytotoxic treatments, and high-risk patients are given the best chance for a cure, maximizing both life expectancy and quality of life.

Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include setiptiline in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as adjuvant therapy with positive airway pressure (PAP) therapy, thereby lowering the pressure required to maintain airway patency during PAP therapy.

The invention provides a conditioning and making method and a high-efficiency even drying method for a small trash fish marine product, belonging to the technical fields of food conditioning and aquatic product processing. The main process of the invention comprises the following steps of: removing three parts (fish scale, fish head and viscera) of a fresh or iced and fresh small trash fish marine product, washing the small trash fish marine product with clear water, slicing the small trash fish marine product into fish chips with the length of 6-10cm, deodorizing preprocessed fish meat for 4hours with compound rinsing fluid, then carrying out ultrasonic assisted vacuum impregnation conditioning (pickling and seasoning), secondary rinsing, draining, medium-short wave infrared drying pre-dehydrating, pulse spraying negative pressure microwave drying, packaging and sterilizing, thus the small trash fish dried fish prepared food product is obtained. The small trash fish marine product disclosed by the invention has good colour, fragrance and taste, beautiful appearance, low moisture content and complete nutrition, is a high-protein and low-fat food, is beneficial to reducing cholesterol and preventing cardiovascular and cerebrovascular diseases after being eaten for a long time, can be used for adjuvant therapy on leukaemia, stomach cancer and the like and is a high-quality leisure food for both the old and the young.

Copy number gains detected in tumors and associated with drug sensitivity and resistance in vivo and in vitro can be used as biomarkers to select, predict and monitor drug treatment outcomes in cancer patients treated with tyrosine kinase inhibitors. Methods to identify patients with NSCLC or other malignancies who are more likely to benefit from tyrosine kinase inhibitors such as VEGF or VEGFR inhibitors when used either as monotherapy or in combination with other therapies such as chemotherapy or EGFR inhibitors, and who are in the advanced stages of disease and / or who have undergone adjuvant therapy are also provided herein.

The invention discloses a computer-assisted psychological consulting automatic question-answering robot system and relates to a robot system for psychological consulting. The system aims to solve the problems that existing adjuvant therapy equipment of psychological consultants is incapable of working independently, feeding consultation back and monitoring in real time, feeding consulting results back timely and building psychological consulting files of the whole process of the consulting therapy and is not strong in expansibility. According to the system, a psychological consulting question feature extraction module is used for extracting key features of psychological consulting questions input by users; a dialogue control logic module is used for reading and processing the extracted key features and giving a candidate answer set; a knowledge base of the robot system is used for storing answers of the psychological consulting questions; a dialogue historical analysis module is used for analyzing the dialogue history of the psychological consulting users; an answering management module is used for giving a best psychological consulting answer according to the dialogue history; and an answering generating module is used for outputting the best answer and storing the answer into a dialogue journal. The system disclosed by the invention is used for assisting the psychological consulting.

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and / or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Methods of using zonisamide as an adjunctive therapy for partial seizures are disclosed. In particular, the methods enhance the safety of patients taking pharmaceutical formulations of zonisamide by providing information that increases the awareness of pancreatitis as a possible side effect; wherein the patients and / or prescribing physicians and other medical care providers are advised to monitor for pancreatitis and employ methods that will improve the therapeutic outcome in the few patients who experience pancreatitis associated with zonisamide therapy.

The present invention provides for improved vectors for use in gene therapy. Utilizing the cancer specific DF3 / MUC1 promoter to drive a replication essential gene, vectors are made conditionally replication-competent, permitting wider infection and expression of tumor cells. In addition, therapeutic genes and adjunct therapies further increase anti-tumor efficacy.

The present invention relates to a new method of adjuvant therapy in the treatment of early breast cancer, comprising administering six cycles of docetaxel, doxorubicin and cyclophosphamide to a patient in need thereof, wherein said dosages have a marked therapeutic effect when compared to other adjuvant therapies.

Methods of using zonisamide as an adjunctive therapy for partial seizures are disclosed. In particular, the methods enhance the safety of patients taking pharmaceutical formulations of zonisamide by providing information that increases the awareness of pancreatitis as a possible side effect; wherein the patients and / or prescribing physicians and other medical care providers are advised to monitor for pancreatitis and employ methods that will improve the therapeutic outcome in the few patients who experience pancreatitis associated with zonisamide therapy.

The invention belongs to the field of remote control and artificial intelligence and relates to an intelligent adjuvant therapy robot device for performing real-time social capability training for autism children. The device comprises a head movement driver (1), an arm movement driver (2), a device loader (3), a driving-driven wheel type chassis (4) and a casing module (7). A multi-joint combined driving mode is adopted, the collaborated driving capability of the robot for every movement joint is improved, the problem that time delay affects the interaction effect is solved, precise posture control of the robot in the random direction is achieved, a limb movement path planning function for automatically avoiding obstacles is achieved, and intelligent emotion interaction between a human and the robot and a safe and reliable family remote rehabilitation therapy model are achieved in various modes such as voice, images, touch and induction in the man-machine interactive process in response to emotion cognitive disorder which occurs universally in child patients.

The invention provides a method and a system with a sleeping aid function and a cellphone integrated with the system. The method includes acquiring brain wave signals; analyzing the brain wave signals and judging whether sleeping needs aid if the brain wave signals stay in a first preset state; wirelessly coupling the brain wave signals in the first preset state by the electromagnetic waves of the second preset state, so that the brain wave signals of the first preset state are adjusted into brain wave signal states in a tight sleep. The system comprises a brain wave acquiring module, a processing module and an electromagnetic wave coupling module. By the method and the system, sleeping can receive better adjuvant therapy, and adverse effect such as sound and light is avoided.

The invention is a functional skin care product containing purslane extractive. Raw materials of the functional skin care product include, by weight, 10 parts of purslane extractive, 1-2 parts of Prinsepia utilis rogle oil, 2-5 parts of glycerol, 0.3-0.5 parts of crylic acid (ester) / C10-30 alkanol acrylate cross-linked polymer, 2-3 parts of 1,2-pentanediol, 1-5 parts of synthesized squalane, 1-2 parts of tocopheryl acetate, 2-3 parts of cetostearyl alcohol, 0.1-0.2 part of allantoin, 0.3-0.8 part of sodium hyaluronate, 3-5 parts of Butyrospermum parkii butter, and 100 parts of deionized water. Or the Prinsepia utilis rogle oil and the Butyrospermum parkii butter are not added. By the aid of animal experiments, namely, mouse auricle swelling models due to dimethlbenzene, the functional skin care product containing purslane extractive is fine in anti-inflammation and anti-allergy effects, mild in nature and fine in safety, and is free of toxic reaction and anaphylaxis. The functional skin care product has an adjuvant therapy function to skin barrier recovery of common discosmetic dermatosis such as hormone dependent dermatitis and acne, and is fine in curative effect and safety.

The invention discloses an intravascular stent with complex functions. The intravascular stent comprises a stent main body which is mesh-shaped and can be released from and retracted to a feeding catheter, wherein a near end of the stent main body is openly conical, the middle part of the stent main body is circular tube-shaped, and a far end of the stent main body has a closed structure; and the stent main body has a mesh shape which is woven by single wires or a plurality of wires or is engraved by a laser engraving machine. The stent which is taken as an acute thrombus removal system can quickly and efficiently take out thrombi, and can also capture small thrombi which flow toward the far end so as to avoid secondary stroke caused by the thrombus blockage of the far end; the stent which is taken as a temporary stent expands intracranial blood vessels or narrow and blocked blood vessels on other parts of human bodies, plays the effects of dredging and reconstructing blood flow, and can capture small thrombi or emboli; and the stent which is taken as a long-term implanted stent performs adjuvant therapy on arterial aneurysms of furcations, and fills in a market gap. If the position of the stent is not satisfactory, the entire stent can be retracted to the feeding catheter, and is released again. The maneuverability of the stent is high, so the operation difficulty is reduced, and the surgical success rate is greatly improved.

The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®.

The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor antagonist. The methods of the present invention are useful in reducing pain, such as traumatic pain, neuropathic pain, organ pain and / or pain associated with diseases. The P2X receptor antagonists useful for this invention are non-nucleotide compounds of general Formula I. Compounds of Formula I can be used alone to treat pain. Compounds of Formula I can also be used in conjunction with other therapeutic agents or adjunctive therapies commonly used to treat pain, thus enhancing the therapeutic effect of pain reduction.

A method for enhancing glycemic control and / or insulin sensitivity in a human subject having diabetic nephropathy and / or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and / or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and / or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

In an attempt to improve primary disease responsiveness and / or to overcome resistant disease, the present disclosure provides a method for treating or inhibiting the proliferation of a WT-1-dependent cancer comprising providing to a subject in need thereof a therapeutically effective amount of a tyrosine kinase inhibitor along with an anti-WT-1 / HLA antibody, that is, an antibody that specifically binds to a peptide of Wilms' tumor protein (WT-1) presented on the surface of the cancer cells in an HLA-restricted fashion.